Flexyx

Flexyx drugs: Miacalcin (Novartis)

Miacalcin (Novartis) - General Information:

Synthetic peptide, 32 residues long formulated as a nasal spray.

Pharmacology:

Calcitonin inhibits bone removal by osteoclasts (bone remodeling cells) and promotes bone formation by osteoblasts. This leads to a net increase in bone mass. Calcitonin also reduces plasma calcium levels and enhances secretion of ions in the kidney.

Miacalcin (Novartis) for patients

Nasal Spray:

Careful instructions on pump assembly, priming of the pump and nasal introduction of Calcitonin (salmon) nasal spray should be given to the patient. Although instructions for patients are supplied with individual bottles, procedures for use should be demonstrated to each patient. Patients should notify their physician if they develop significant nasal irritation.

Patients should be advised of the following:

• Store new, unassembled bottles in the refrigerator between 2°C-8°C (36°F-46°F).
• Protect the product from freezing.
• Before priming the pump and using a new bottle, allow it to reach room temperature.
• Store bottle in use at room temperature between 15°C-30°C (59°F-86°F) in an upright position, for up to 35 days. Each bottle contains at least 30 doses.
• See MANUAL, Priming (Activation) of Pump for complete instructions on priming the pump and administering Miacalcin® Nasal Spray. You should keep track of the number of doses used from the bottle. After 30 doses, each spray may not deliver the correct amount of medication, even if the bottle is not completely empty.

Injection:

Careful instruction in sterile injection technique should be given to the patient, and to other persons who may administer Miacalcin® (calcitonin-salmon) Injection, Synthetic.

Miacalcin (Novartis) Interactions

Nasal Spray: Formal studies designed to evaluate drug interactions with Calcitonin (salmon) have not been done. No drug interaction studies have been performed with Calcitonin (salmon) nasal spray ingredients.

Currently, no drug interactions with Calcitonin (salmon) have been observed. The effects of prior use of diphosphonates in postmenopausal osteoporosis patients have not been assessed; however, in patients with Paget's Disease prior diphosphonate use appears to reduce the anti-resorptive response to Calcitonin (salmon) nasal spray.

Miacalcin (Novartis) Contraindications

Clinical allergy to (synthetic) Calcitonin (salmon).

Additional information about Miacalcin (Novartis)

Miacalcin (Novartis) Indication: For the treatment of post-menopausal osteoporosis
Mechanism Of Action: Calcitonin binds to the calcitonin receptor (found primarily in osteoclasts) which then enhances the production of vitamin D producing enzymes (25-hydroxyvitamine D-24-hydroxylase), leading to greater calcium retention and enhanced bone density. Binding of calcitonin to its receptor also activates adenylyl cyclase and the phosphatidyl-inositol-calcium pathway.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Salmon Calcitonin
Synonyms: Calcitonin 1 precursor; Salmotonin; Calcitonin, salmon; Calcitonin-salmon
Where to order Salmon Calcitonin (and Miacalcin (Novartis) analogs) online:
Drug Category: Antiosteporotic Agents; Antihypocalcemic Agents; Bone Density Conservation Agents
Drug Type: Biotech; Approved; Investigational
Other Brand Names containing Salmon Calcitonin: Miacalcin (Novartis); Calcimar;
Absorption: Salmon calcitonin is rapidly absorbed and eliminated. Bioavailability following subcutaneous and intramuscular injection in humans is high and similar for the two routes of administration (71% and 66%, respectively).
Toxicity (Overdose): Salmon calcitonin is devoid of embryotoxic, teratogenic and mutagenic potential.
Protein Binding: 30 to 40%
Biotransformation: Salmon calcitonin is primarily and almost exclusively degraded in the kidneys, forming pharmacologically inactive fragments of the molecule.
Half Life: 50-80 minutes
Dosage Forms of Miacalcin (Novartis): Liquid Intramuscular
Solution Intramuscular
Solution Nasal
Liquid Nasal
Chemical IUPAC Name: 4-[[5-amino-2-[[2-[[2-[[6-amino-2-[[2-[[2-[[2-[[22-amino-16-(2-amino-2-oxoethyl)-7-(1-hydroxyethyl)-10,19-bis(hydroxymethyl)-13-(2-methylpropyl)-6,9,12,15,18,21-hexaoxo1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-[[1-[[1-[[6-amino-1-[[1-[[5-amino-1-[[1-[[1-[2-[[1-[[1-[[4-amino-1-[[1-[[2-[[1-[[2-[[1-(2-carbamoylpyrrolidin-1-yl)-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(3H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
Chemical Formula: C145H240N44O48S2
Salmon Calcitonin on Wikipedia: http://en.wikipedia.org/wiki/Calcitonin
Organisms Affected: Humans and other mammals